Donepezil is a once-daily Alzheimer dementia drug that supports memory and attention, and treatment starts at 5 mg each evening. It usually rises to 10 mg after 4-6 weeks, and 23 mg is only for moderate-to-severe disease after 3 months on 10 mg. The choice rests on disease stage, time on the current dose, and tolerance. A higher dose does not work faster, and it raises gut and heart effects.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does everyone start at 5 mg?
- When does 10 mg become the target?
- Who is 23 mg for, and what does it add?
- What should you watch when the dose rises?
Why does everyone start at 5 mg?
According to the Eisai Aricept FDA label, treatment starts at 5 mg once daily in the evening just before retiring for all Alzheimer dementia stages. That low start lets the body adjust before any increase. Families can use those first weeks to learn the routine and note appetite, nausea, sleep, and pulse.
A steady evening time helps missed doses stand out. It also makes side effects easier to link to the drug. Do not advance early because good days return.
When does 10 mg become the target?
The same FDA label states patients may advance to 10 mg once daily after 4-6 weeks on 5 mg. For mild-to-moderate Alzheimer disease, 10 mg per day is the maximum. Staying at 5 mg longer is reasonable when nausea, vomiting, diarrhea, or slow pulse appear.
Clinicians prefer the slower 6-week change because steady state takes about 15 days, according to the same FDA label. A 1-week jump reaches full effect before tolerance is clear. Waiting gives caregivers time to report vomiting, stomach pain, black stools, fainting, or unusual fatigue.
Who is 23 mg for, and what does it add?
According to the DailyMed donepezil label, the 23-mg once-daily tablet is restricted to moderate-to-severe Alzheimer disease after at least 3 months of stable 10 mg daily treatment. It is not a next step for mild disease. The Eisai and Pfizer approval notice says FDA approved it in July 2010 after a head-to-head trial in over 1,400 patients.
In that 24-week trial, 23 mg improved cognition more than 10 mg on the Severe Impairment Battery, according to an American Family Physician summary, about 2.6 points versus 0.4 points. The limit matters as much as the gain. A 2013 BMC Geriatrics analysis of that trial found no significant between-dose difference in global functioning, about 4.23 versus 4.29.
What should you watch when the dose rises?
Dose escalation markedly raises gut toxicity, according to the Lupin label, with nausea in 11.8% versus 3.4% and vomiting in 9.2% versus 2.5% for 23 mg versus 10 mg. Most 23-mg stops happened in the first month. Weight loss is also expected on 23 mg.
The FDA label advises watching for vomiting, stomach bleeding, slow heartbeat, and heart block during any increase. Caregivers can keep one short daily note for the first month. Call the care team the same day if vomiting blocks fluids, stools turn black, or the pulse feels unusually slow.
- vomiting, ongoing nausea, diarrhea, or poor fluids
- black or bloody stools, vomit that looks like coffee grounds, or new stomach pain
- very slow pulse, dizziness, fainting, or new shortness of breath
- steady weight loss or clothes fitting looser
